ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO ...

Key takeaways: Young adults with colorectal cancer require multidisciplinary care that addresses fertility preservation and other unique needs. Aggressive treatment based solely on age at ...

Seeking high-thermal-conductivity materials is a route to enhancing the efficiency of heat dissipation in Ga-based high-power-density devices. In this work, we use first-principles calculations with ...

WALTHAM, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), today announced the June 20, 2025 updated National Comprehensive Cancer Network ® (NCCN ®) Clinical Practice Guidelines ...

NCCN Clinical Practice Guidelines in Oncology for the Prevention and Treatment of Cancer-Related Infections now recommend monoclonal antibodies for pre-exposure prophylaxis against COVID-19 in ...

National Comprehensive Cancer Network® (NCCN®) Guidelines Recommend Monoclonal Antibodies for COVID-19 Prevention in People with Cancer; New Data Published in JAMA Oncology Underscore Severe ...

NCCN Clinical Practice Guidelines in Oncology for the Prevention and Treatment of Cancer-Related Infections now recommend monoclonal antibodies for pre-exposure prophylaxis against COVID-19 in ...

Systematic mediastinal lymph node dissection (LND) or sampling is currently recommended for patients with early-stage non–small cell lung cancer. We aimed to investigate whether no mediastinal LND was ...

Although IntAct did not show a significant benefit for ICG fluorescence angiography, a signal towards a reduction in clinical anastomotic leak rate was observed. The benefit of ICG could be in ...

Primary results from the phase 2 RAMP 201 trial (NCT04625270) evaluating the combination therapy of avutometinib and defactinib (Avmapki Fakzynja co-pack) for patients with KRAS- mutated recurrent low ...

During a live event, Sumanta K. Pal, MD, discussed second-line renal cell carcinoma therapies, in the context of a patient with post-immunotherapy progression.